Melanotan II (MT-2): Research, Mechanism, and What the Evidence Actually Shows
A plain review of what Melanotan II does, what the small human trials found, and what nobody has studied.
Small human trials of roughly 10 to 30 volunteers measured skin darkening after injection; long-term safety has never been studied in any controlled setting.
- Studied for
- Sunless tanning, Sexual arousal, Appetite suppression
- Route
- subcutaneous injection
- Status
- Research chemical; not approved anywhere
What it is
Melanotan II, usually shortened to MT-2, is a lab-made peptide hormone. A peptide is a short chain of amino acids, the building blocks of protein, and this one works by switching on a family of receptors called melanocortin receptors. Researchers at the University of Arizona built it in the 1980s to make skin tan without sunlight, hoping that would lower skin cancer risk.
It copies a natural hormone called alpha-melanocyte-stimulating hormone, which helps control skin color, appetite, and sexual function. MT-2 is folded into a ring, so the body breaks it down more slowly than the natural hormone and it acts more strongly.
The design did not work out as planned. MT-2 turns on several melanocortin receptors at once, not just the one for skin color. No regulator anywhere has approved it, yet it is one of the most widely self-injected research peptides in the world. This page reviews the evidence; it is not a guide to using it.
What it is studied for
Tanning is the original purpose. MT-2 acts on MC1R, a receptor found on melanocytes, the skin cells that make pigment. When the receptor is switched on, the cells make more pigment, the same thing that happens after sun exposure. Fair-skinned people have MC1R variants that make less pigment, and MT-2 can partly override that by pushing hard on whatever receptor activity exists.
Sexual arousal is the second use. The MC4R receptor sits in the hypothalamus, the part of the brain that governs hunger, sex drive, and energy use, and MT-2 switches it on. That same receptor is why MT-2 also lowers appetite, the third area of interest.
The arousal effect was strong enough that drug developers built PT-141 (bremelanotide) from MT-2 to isolate it. MT-2 also acts on MC3R, which is involved in energy balance and inflammation, and on MC5R, which affects the skin’s oil glands. Neither of those roles is well understood.
This spread of effects is what pharmacologists call off-target effects, meaning the drug hits receptors beyond the one it was aimed at. MT-2 is a receptor agonist, a compound that turns receptors on rather than blocking them. Once injected it travels everywhere and activates every melanocortin receptor it reaches, so a person using it for a tan gets the arousal, the nausea, and the appetite loss in the same package.
What the evidence actually shows
In humans
MT-2 has been tested in a handful of small trials. In a 1996 pilot study, Dorr and colleagues injected fair-skinned volunteers under the skin and measured a clear, dose-related darkening with a light-reflectance instrument, with no sun exposure involved (Dorr et al., 1996).
A later trial confirmed the effect and found that MT-2 plus ultraviolet light produced more pigment than ultraviolet light alone (Barnetson et al., 2006). These studies enrolled small groups, typically 10 to 30 people, but the tanning was consistent and objectively measured.
During those early tanning trials, male volunteers reported spontaneous erections. That accidental finding redirected a line of drug research and produced PT-141. Formal human testing of MT-2 itself for sexual function is thin; most of what we know comes from those incidental reports and from the later PT-141 program, which confirmed the MC4R mechanism.
Trial participants have also reported less appetite, which fits what MC4R does. MT-2 has never been formally tested as a weight-loss agent in people.
In animals
Animal work fills in the mechanism. MT-2 darkens skin in several species, as expected from MC1R. In rodents and primates it raises sexual motivation and mating behavior, which supports the MC4R explanation (Wessells et al., 2003).
Rodents given MT-2 also eat less, consistent with the melanocortin system’s role in energy balance. In animal models of erectile dysfunction, MT-2 improved erectile response.
From user reports
People who use MT-2 describe strong, sometimes unwelcome arousal alongside reduced hunger, plus nausea and flushing after each injection. Many say the nausea fades with repeated use. These are self-reports, not trial data, and we cannot separate the peptide’s effect from expectation or from whatever else those users were doing.
What has not been shown
Nobody has shown that MT-2 tanning protects against ultraviolet damage. Pigment type and how it is distributed both matter, and MT-2 tanning may not behave like a natural tan. Long-term safety has never been studied in a controlled setting, the cancer question is open, and no dose-finding trial has established a proper dose.
How it is used in studies
Study participants received MT-2 by injection under the skin, because the digestive tract would destroy it if swallowed. The pharmacokinetics, meaning how the body absorbs, spreads, and clears the drug, have only been studied in limited clinical settings.
Its ring shape makes it more stable than the natural hormone, so it lingers longer and keeps the receptors active for longer. Tanning builds up over repeated doses, while the immediate effects of nausea, flushing, and arousal usually appear within hours of each injection. The 1996 trial reported a dose-related response, but the published studies do not add up to an established dose, and we are not reporting one here.
Side effects and unknowns
Nausea is the most common complaint. It can be significant at first or at higher doses, seems to come from melanocortin receptors in the brainstem and gut, and often eases with repeated use. Facial flushing, meaning warmth and redness within minutes to hours, is also common.
Reduced appetite and sexual arousal are direct effects of the peptide rather than side effects in the usual sense. Some users welcome them and others do not. Injection-site redness or swelling, fatigue, and yawning are also reported, and the yawning has no clear explanation.
Skin changes are the bigger worry. MT-2 stimulates every melanocyte it reaches, including those in existing moles. Published case reports describe moles darkening and new moles appearing during use, and a few describe atypical moles. That creates a diagnostic problem, because a changing mole is also the classic warning sign of melanoma.
Melanoma is a cancer of melanocytes, the same cells MT-2 stimulates. Whether long-term stimulation can trigger that cancer, speed up one that already exists, or simply hide its early signs has not been tested. Case reports of melanoma in MT-2 users exist, but case reports cannot prove cause.
Clinical studies have observed short-lived rises in blood pressure. Beyond that, the long-term picture is blank. No study has followed users for years, so the concerns about cancer, chronic melanocyte stimulation, immune effects, and heart and blood vessel effects all remain theoretical.
Not knowing whether something is dangerous is different from knowing it is safe. Our peptide safety guide covers that distinction in more depth.
A few more gaps deserve naming. Some users say mole changes persist after they stop, and whether those changes are permanent is not documented. Many users combine MT-2 with tanning beds or sunlight, and nobody has studied whether the combination adds risk. People with fair skin, many moles, or a family history of melanoma have no data at all.
Legal status
No regulator has approved MT-2 for anything. The US FDA has not approved it as a drug, supplement, or cosmetic ingredient, and has issued warnings about MT-2 products. The European Medicines Agency has not approved it either, and several national regulators in Europe have warned against unlicensed products.
Australia’s Therapeutic Goods Administration has issued repeated warnings, calling it an unregistered product with unproven safety and effectiveness. The World Anti-Doping Agency bans it under section S2 of its Prohibited List, which covers peptide hormones and related substances, so athletes who test positive face a doping violation.
Vendors sell it online labeled “research chemical” or “not for human consumption.” That label means no manufacturing standards, no purity requirements, and no system for tracking side effects.
Bottom line
MT-2 reliably darkens skin, and small human trials have measured it. It also causes arousal, lower appetite, and nausea, because it hits several receptors at once. Whether years of use raise melanoma risk is unknown, and nobody has done the study that would tell us.
Frequently Asked Questions
Is Melanotan II the same as PT-141?
No. PT-141 (bremelanotide) was derived from MT-2 and modified to act more selectively on MC4R, the receptor behind sexual desire. PT-141 went through full FDA clinical development and is approved as Vyleesi for low sexual desire in women. MT-2 is the broader parent compound, causes more tanning, and has never been approved.
Can MT-2 cause melanoma?
Nobody has proven or disproven it. MT-2 stimulates melanocytes, the cell type that becomes melanoma, and case reports describe melanoma in users, but case reports cannot show cause. The concern is plausible and the long-term data does not exist. Anyone with melanoma risk factors should treat it with particular caution.
Does MT-2 provide protection against UV damage?
We don’t know. MT-2 raises pigment, but whether that pigment blocks UV damage to DNA has not been demonstrated, since the type, spread, and amount of pigment all matter. An MT-2 tan should not be treated as sunscreen.
Why is MT-2 still widely used if it’s not approved?
It gives a tan without sun, costs little, is easy to buy from online research chemical vendors, and its effects are obvious and reinforcing. Being sold as “not for human consumption” while humans consume it is a gap shared by many research peptides.
Can the nausea be avoided?
People who use it report that lower doses, working up gradually, and timing around meals make nausea milder, and that it often fades with repeated use. It is a direct effect of the receptors MT-2 activates, not a sign of impurity, so it cannot be fully eliminated in everyone at effective doses.
How is MT-2 different from Melanotan I?
Melanotan I, also called afamelanotide, acts more selectively on MC1R, so it tans with less arousal and less nausea. It is approved in some markets as Scenesse, cleared by the EMA for a rare light-sensitivity disorder called erythropoietic protoporphyria. MT-2 is the less selective compound with wider receptor activity.
References
- Dorr RT, et al. “Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.” Arch Dermatol. 2004;140(7):827-35. PubMed
- Dorr RT, et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sci. 1996;58(20):1777-84. PubMed
- Barnetson RS, et al. “[Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers.” J Invest Dermatol. 2006;126(8):1869-78. PubMed
- Wessells H, et al. “Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.” Int J Impot Res. 2003;15 Suppl 5:S72-5. PubMed
- Pfaus JG, et al. “A review of animal and human data on the melanocortin system and sexual function.” Eur J Pharmacol. 2013;704(1-3):270-9. PubMed
- Brennan R, et al. “Melanotan II as a lifestyle drug — an overview.” Perform Enhanc Health. 2014;3(2):78-85.
- Reid C, Fitzgerald T. “Adverse effects associated with the use of Melanotan.” Ir Med J. 2013;106(5):148-9.
- Langan EA, et al. “Darkening of pre-existing melanocytic naevi and development of new naevi with the use of Melanotan-II.” Br J Dermatol. 2009;161(3):707-8.